Compare Ascendis Pharma A/S (ASND) vs Microsoft (MSFT) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Ascendis Pharma A/S vs Microsoft — how do they compare? Ascendis Pharma A/S trades at $270.99 (market cap $17.74B), while Microsoft trades at $386.97 (market cap $2.86T). The key difference: Microsoft is far larger — about 161.2× Ascendis Pharma A/S's market cap, and Microsoft pays a 0.95% dividend while Ascendis Pharma A/S pays none. Which is the better fit depends on your goals.
| ASND | MSFT | |
|---|---|---|
Market Cap | $17.74B | $2.86T |
Sector | Health | Technology |
52-Week High | $277.18 | $542.07 |
52-Week Low | $163.32 | $352.83 |
Enterprise Value | $18.11B | $2.84T |
Volume | — | 36,654,621 |
Dividend Yield | — | 0.95% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ascendis Pharma (ASND) trades at $270.45, down 1.81% on the day, with a bullish technical outlook supported by moving averages and positive analyst sentiment. The company reported Q1 2026 revenue of $241 million (converted from €197 million for YORVIPATH and €44 million for SKYTROFA, Q1 2026 earnings report May 7, 2026) and beat EPS expectations, while recent news highlights clinical progress in achondroplasia and hypoparathyroidism treatments. Valuation ratios are elevated with a P/E of 31.38 and P/S of 16.94, reflecting growth expectations.
The outlook is positive due to strong revenue growth, multiple product launches, and a 92% analyst buy rating with a $321.17 price target. Key risks include high debt levels, persistent net losses despite improving margins, and reliance on successful commercialization of new therapies. The stock's upside depends on execution of growth strategy and achieving profitability.
Microsoft (MSFT) trades at $385.10, up 0.19% on the day, with a bearish technical signal despite strong fundamentals. The company reported Q1 2026 EPS of $4.27, beating estimates, and maintains robust profitability with a 39.34% net income margin. Recent news highlights AI leadership and Azure momentum, though concerns over capital expenditures weigh on sentiment.
Outlook remains positive with an 80.49% analyst buy rating and a $548.87 consensus price target, implying significant upside. Risks include competitive pressures in AI, geopolitical tensions, and high valuation multiples. Long-term growth driven by cloud and AI investments supports a constructive view for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Ascendis Pharma A/S
Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates mainly in North America, Germany, China, and Denmark and derives the majority of its revenue from China.
Read more on ASND →About Microsoft
Microsoft Corporation develops, manufactures, licenses, sells, and supports software products. The Company offers operating system software, server application software, business and consumer applications software, software development tools, and Internet and intranet software. Microsoft also develops video game consoles and digital music entertainment devices.
Read more on MSFT →
